<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Mefenamic acid</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00784</strong>&#160; (APRD00730)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00784/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00784/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00784.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00784.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00784.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00784.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00784.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00784">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Acide m&#233;f&#233;namique</td><td>French</td><td>DCF</td></tr><tr><td>Acido mefenamico</td><td>Spanish</td><td>INN</td></tr><tr><td>Acidum mefenamicum</td><td>Latin</td><td>INN</td></tr><tr><td>Mefenamins&#228;ure</td><td>German</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Coslan</td><td>Parke Davis</td></tr><tr><td>Lysalgo</td><td>SIT</td></tr><tr><td>Mefacit</td><td>SecFarm</td></tr><tr><td>Parkemed</td><td>Pfizer</td></tr><tr><td>Ponalar</td><td>Coronet Crown</td></tr><tr><td>Ponstan</td><td>Pfizer</td></tr><tr><td>Ponstan Forte</td><td>Pfizer</td></tr><tr><td>Ponstel</td><td>Adcock Ingram Pharmaceuticals</td></tr><tr><td>Ponstyl</td><td>Pfizer</td></tr><tr><td>Ponstyl Fort</td><td>Pfizer</td></tr><tr><td>Pontal</td><td>Daiichi Sankyo</td></tr><tr><td>Tanston</td><td>Pfizer</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Mepar</td><td>Mefenamic Acid and Paracetamol</td></tr><tr><td>Paraspas</td><td>Mefenamic Acid and Dicycloverine</td></tr><tr><td>Reotran-MF</td><td>Mefenamic Acid and Tranexamic Acid</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-inflammatory-agents-non-steroidal">Anti-Inflammatory Agents, Non-Steroidal</a></li>
<li><a href="/mesh/cyclooxygenase-inhibitors">Cyclooxygenase Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>61-68-7</td></tr><tr><th>Weight</th><td>Average: 241.2851<br>Monoisotopic: 241.110278729</td></tr><tr><th>Chemical Formula</th><td>C<sub>15</sub>H<sub>15</sub>NO<sub>2</sub></td></tr><tr><th>InChI Key</th><td>HYYBABOKPJLUIN-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-[(2,3-dimethylphenyl)amino]benzoic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Benzoic Acid and Derivatives</td></tr><tr><th>Direct parent</th><td>Aminobenzoic Acid Derivatives</td></tr><tr><th>Alternative parents</th><td>Benzoic Acids; Benzoyl Derivatives; Toluenes; Polyamines; Carboxylic Acids; Secondary Amines; Enolates</td></tr><tr><th>Substituents</th><td>benzoyl; toluene; secondary amine; carboxylic acid derivative; enolate; carboxylic acid; polyamine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the aminobenzoic acid derivatives. These are benzoic acids (or derivative thereof) containing an amine group attached to the benzene moiety.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of rheumatoid arthritis, osteoarthritis, dysmenorrhea, and mild to moderate pain, inflammation, and fever.</td></tr><tr><th>Pharmacodynamics</th><td>Mefenamic acid, an anthranilic acid derivative, is a member of the fenamate group of nonsteroidal anti-inflammatory drugs (NSAIDs). It exhibits anti-inflammatory, analgesic, and antipyretic activities. Similar to other NSAIDs, mefenamic acid inhibits prostaglandin synthetase.</td></tr><tr><th>Mechanism of action</th><td>Mefenamic acid binds the prostaglandin synthetase receptors COX-1 and COX-2, inhibiting the action of prostaglandin synthetase. As these receptors have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity, the symptoms of pain are temporarily reduced.</td></tr><tr><th>Absorption</th><td>Mefenamic acid is rapidly absorbed after oral administration.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>1.06 L/kg [Normal Healthy Adults (18-45 yr)]</li>
</ul></td></tr><tr><th>Protein binding</th><td>90%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Mefenamic acid undergoes metabolism by CYP2C9 to 3-hydroxymethyl mefenamic acid, and further oxidation to a 3-carboxymefenamic acid may occur. The activity of these metabolites has not been studied. Mefenamic acid is also glucuronidated directly.</p></td></tr><tr><th>Route of elimination</th><td>The fecal route of elimination accounts for up to 20% of the dose, mainly in the form of unconjugated 3-carboxymefenamic acid.3 The elimination half-life of mefenamic acid is approximately two hours. Mefenamic acid, its metabolites and conjugates are primarily excreted by the kidneys. Both renal and hepatic excretion are significant pathways of elimination.</td></tr><tr><th>Half life</th><td>2 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>Oral cl=21.23 L/hr [Healthy adults (18-45 yrs)]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Oral, rat LD<sub>50</sub>: 740 mg/kg. Symptoms of overdose may include severe stomach pain, coffee ground-like vomit, dark stool, ringing in the ears, change in amount of urine, unusually fast or slow heartbeat, muscle weakness, slow or shallow breathing, confusion, severe headache or loss of consciousness.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Mefanamic Acid Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9156</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.762</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8866</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7948</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8632</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9147</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9191</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.6814</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7019</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9107</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.8949</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9483</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9175</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.6613</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.812
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.5833
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.822
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5445 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9727
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8706
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Shionogi pharma inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.prescript.net">Prescript Pharmaceuticals</a></li>
<li>Professional Co.</li>
<li>Sciele Pharma Inc.</li>
<li><a href="http://www.west-ward.com">West-Ward Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>The NSAID, mefanamic acid, may increase the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB00630">Alendronate</a></td><td>Increased risk of gastric toxicity</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>The NSAID, mefanamic acid, may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB08822">Azilsartan medoxomil</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB00930">Colesevelam</a></td><td>Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. </td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Monitor for nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>The NSAID, mefanamic acid, may increase the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Increases levels of Mefenamic acid via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. </td></tr><tr><td><a href="/drugs/DB01356">Lithium</a></td><td>The NSAID, mefenamic acid, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.</td></tr><tr><td><a href="/drugs/DB00563">Methotrexate</a></td><td>The NSAID, mefenamic acid, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.</td></tr><tr><td><a href="/drugs/DB00675">Tamoxifen</a></td><td>Mefenamic acid may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Mefenamic acid is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>Mefanamic acid, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Mefanamic acid is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00214">Torasemide</a></td><td>Mefanamic acid, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Mefanamic acid is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>The NSAID, Mefenamic acid, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Mefenamic acid is initiated, discontinued or dose changed.  </td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Mefenamic acid. Monitor for increased bleeding during concomitant thearpy. </td></tr><tr><td><a href="/drugs/DB00440">Trimethoprim</a></td><td>The strong CYP2C9 inhibitor, Mefenamic acid, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Mefenamic acid is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Mefanamic acid, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if mefanamic acid is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Mefenamic acid, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of mefenamic acid may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if mefenamic acid is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Take with food.</li></ul></td></tr></tbody></table>